Form 4: Timothy Springer, Director and 10% Owner of Cartesian Therapeutics, Increases Stake in RNAC

Timothy Springer, a Director and 10% owner of Cartesian Therapeutics, has significantly increased his holdings of common stock through a series of transactions between October 2nd and October 4th, 2024.

Summary

• This Form 4 filing details changes in beneficial ownership of Cartesian Therapeutics, Inc. (RNAC) stock by Timothy A. Springer, a director and 10% owner.
• On October 2, 2024, Springer acquired 1,801,314 shares of common stock through a pro rata distribution from TAS Partners LLC.
• Also on October 2, 2024, Springer purchased 5,514 shares at a weighted average price of $17.3779.
• Springer also acquired warrants to purchase 113,587 shares of common stock.
• From October 3-4, 2024, Springer continued purchasing shares in multiple transactions at prices ranging from $17.76 to $24.00, acquiring a total of 151,191 shares.
• These purchases increased Springer's direct holdings of common stock to 8,023,766 shares.
• Springer also has indirect ownership through TAS Partners LLC and shares held by his wife.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A director and significant shareholder increasing their stake suggests confidence in the company's future, but it's important to consider the context of the purchases and the overall financial health of the company.

Positives

• The increased stake by a director and significant shareholder could be interpreted as a positive signal about the company's prospects.
• The purchases were made at increasing prices, suggesting confidence in the company's value.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's future prospects.

Related Party Transactions

• The pro rata distribution from TAS Partners LLC, where Timothy Springer is the managing member, constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the insider buying as a positive signal.
• The increased demand for shares could potentially lead to a short-term increase in the stock price.

Key Dates